<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Larimar Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/larimar-therapeutics-inc</link>
<description>Latest news and press releases for Larimar Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/larimar-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835938b78dffbe2df1035bb.webp</url>
<title>Larimar Therapeutics Inc</title>
<link>https://6ix.com/company/larimar-therapeutics-inc</link>
</image>
<item>
<title>Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 11:00:00 GMT</pubDate>
<description>Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of</description>
</item>
<item>
<title>Larimar Therapeutics to Participate in Upcoming Investor Conferences in March</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-in-march-120</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-in-march-120</guid>
<pubDate>Wed, 04 Mar 2026 21:05:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL. Presentation details can be found below. Leerink Partners Global Healthcare ConferenceDate: Tuesday</description>
</item>
<item>
<title>Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-proposed-dollar75-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-proposed-dollar75-million-underwritten-public-offering</guid>
<pubDate>Wed, 25 Feb 2026 21:01:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriter</description>
</item>
<item>
<title>Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-pricing-of-upsized-dollar100-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-pricing-of-upsized-dollar100-million-underwritten-public-offering</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on</description>
</item>
<item>
<title>Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-fda-breakthrough-therapy-designation-for-nomlabofusp-in-fa-and-reiterates-planned-bla-submission-in-june-2026</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-fda-breakthrough-therapy-designation-for-nomlabofusp-in-fa-and-reiterates-planned-bla-submission-in-june-2026</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data</description>
</item>
<item>
<title>Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-present-44th-annual-130000905</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-present-44th-annual-130000905</guid>
<pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12 – 15, 2026. Details on the presentation can be found below. Date: Wednesday,</description>
</item>
<item>
<title>Larimar Therapeutics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-third-quarter-120000503</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-third-quarter-120000503</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriersConsistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of nomlabofusp to alter FA’s disease course relative to a worsening in a FACOMS natural history study reference populationOf 39 participants in OL study (and of 65 total participants who received at least 1</description>
</item>
<item>
<title>Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-positive-data-110000767</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-positive-data-110000767</guid>
<pubDate>Mon, 29 Sep 2025 11:00:00 GMT</pubDate>
<description>In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4</description>
</item>
<item>
<title>Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-conference-call-210000721</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-conference-call-210000721</guid>
<pubDate>Sun, 28 Sep 2025 21:00:00 GMT</pubDate>
<description>Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDTBALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates for the Company’s nomlabofusp clinical development program including data from the ongoing long-term open label study for the treat</description>
</item>
<item>
<title>Larimar Therapeutics Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-second-quarter-110000151</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-second-quarter-110000151</guid>
<pubDate>Thu, 14 Aug 2025 11:00:00 GMT</pubDate>
<description>Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp clinical studies are currently screening and enrolling in the open label study; planning to enroll children (2 to 11 years of age) directly into the open label studyFDA recommended that the safety database include at least 30 participants with con</description>
</item>
<item>
<title>Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-closing-underwritten-201500112</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-closing-underwritten-201500112</guid>
<pubDate>Thu, 31 Jul 2025 20:15:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,812,500 additional shares, at the public offering price of $3.20 per share. The aggregate</description>
</item>
<item>
<title>Larimar Therapeutics Announces Pricing of Underwritten Public Offering</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-pricing-underwritten-035000933</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-pricing-underwritten-035000933</guid>
<pubDate>Wed, 30 Jul 2025 03:50:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting</description>
</item>
<item>
<title>Larimar Therapeutics Announces Proposed Underwritten Public Offering</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-proposed-underwritten-200100054</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-proposed-underwritten-200100054</guid>
<pubDate>Tue, 29 Jul 2025 20:01:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day opti</description>
</item>
<item>
<title>Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-publishes-nonclinical-data-110000538</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-publishes-nonclinical-data-110000538</guid>
<pubDate>Tue, 08 Jul 2025 11:00:00 GMT</pubDate>
<description>Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed</description>
</item>
<item>
<title>Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-fda-recommendations-110000720</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-fda-recommendations-110000720</guid>
<pubDate>Mon, 23 Jun 2025 11:00:00 GMT</pubDate>
<description>Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLAWritten FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for a</description>
</item>
<item>
<title>Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-regulatory-call-200500270</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-regulatory-call-200500270</guid>
<pubDate>Fri, 20 Jun 2025 20:05:00 GMT</pubDate>
<description>Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDTBALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company’s nomlabofusp clinical development program for the treatment of Friedreich’s Ataxia on Monday, June 23, 2025 a</description>
</item>
<item>
<title>Larimar Therapeutics Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-first-quarter-110000276</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-reports-first-quarter-110000276</guid>
<pubDate>Wed, 30 Apr 2025 11:00:00 GMT</pubDate>
<description>FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025 Strong balance she</description>
</item>
<item>
<title>Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-provides-nomlabofusp-development-110000420</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-provides-nomlabofusp-development-110000420</guid>
<pubDate>Mon, 24 Mar 2025 11:00:00 GMT</pubDate>
<description>FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approvalFDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as heart, dorsal root ganglia and</description>
</item>
<item>
<title>Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-present-leerink-partners-210500481</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-present-leerink-partners-210500481</guid>
<pubDate>Mon, 03 Mar 2025 21:05:00 GMT</pubDate>
<description>BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025. Details on the presentation can be found below. Date: Monday, March</description>
</item>
<item>
<title>Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia</title>
<link>https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-dosing-of-adolescents-in-nomlabofusp-pediatric-pharmacokinetic-run-in-study-for-patients-with-friedreichs-ataxia</link>
<guid isPermaLink="true">https://6ix.com/company/larimar-therapeutics-inc/news/larimar-therapeutics-announces-dosing-of-adolescents-in-nomlabofusp-pediatric-pharmacokinetic-run-in-study-for-patients-with-friedreichs-ataxia</guid>
<pubDate>Thu, 23 Jan 2025 05:00:00 GMT</pubDate>
<description>Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK)</description>
</item>
</channel>
</rss>